Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD-(L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer. The US regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results